{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gonorrhoea/prescribing-information/quinolones-ciprofloxacin-or-ofloxacin/","result":{"pageContext":{"chapter":{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)","depth":2,"htmlHeader":"<!-- begin field 1b499d1c-5ebc-44e5-82d7-5c0c890a51dc --><h2>Quinolones (ciprofloxacin or ofloxacin)</h2><!-- end field 1b499d1c-5ebc-44e5-82d7-5c0c890a51dc -->","summary":"","htmlStringContent":"<!-- begin item 17a5a70c-0a75-4d50-8fb7-51f1123da732 --><!-- end item 17a5a70c-0a75-4d50-8fb7-51f1123da732 -->","topic":{"id":"8aeba2d1-9f1a-5428-a119-41fa94223706","topicId":"4b4cdbb6-97a0-4b13-a04c-d857b72bcddf","topicName":"Gonorrhoea","slug":"gonorrhoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"803822d1-16b6-5c36-b47d-9a6e8e236c06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d98590-b989-554f-8ccb-804279dab0d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4ac6e3b9-f31e-5367-b177-171c1cd87bd7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"41812e79-dbe3-5991-8344-05de91dff192","slug":"changes","fullItemName":"Changes"},{"id":"bbabf43d-27dd-5795-b02b-9891c7e9e7ca","slug":"update","fullItemName":"Update"}]},{"id":"cd231f06-b527-5de3-a8cb-277fd6f84587","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"858e0da7-8025-510b-ac87-1055c9b510e0","slug":"goals","fullItemName":"Goals"},{"id":"b9efda8e-7814-5479-af6b-1272844f3546","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"874bc02c-2022-584f-bc91-b99489f3ac6c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"17fcc032-43d9-5c38-b19b-e10bef0648f1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1033f77b-d5e5-5700-b7f9-f314bb1daef3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"11e8f7de-1c3f-5692-a9e4-f2c1645e1023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f889ee27-2135-5f9e-b131-fb46452febe4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"55283c6e-a75b-5deb-8827-406245e897ff","slug":"definition","fullItemName":"Definition"},{"id":"cf7e0416-d49c-57de-8063-ebf536922bcc","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6c929d32-5621-5a53-9e9b-63a3e1523e20","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1196a066-1188-5938-b1d3-932dd0ffc403","slug":"complications","fullItemName":"Complications"}]},{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a9a1ae79-f8a2-59e3-a720-8207d27eee47","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee9cef7-bd86-583b-9d57-f5d8f9a5d6d0","slug":"signs-symptoms-in-a-man","fullItemName":"Signs and symptoms in a man"},{"id":"9b460f20-3213-5956-896f-ccc5156c9d32","slug":"signs-symptoms-in-a-woman","fullItemName":"Signs and symptoms in a woman"},{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis"},{"id":"44933641-db44-5935-9459-ea8e78869d57","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"e0f6f6d2-d4a8-5801-b817-0588e8540a04","slug":"possible-sexual-abuse","fullItemName":"Possible sexual abuse"}]},{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","fullItemName":"Management","slug":"management","subChapters":[{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"98eac615-b29a-5de3-a795-37b42615eb61","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)"},{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)"},{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39f7e7ee-870b-55c8-9cd9-55320d487f24","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05886abb-50fd-51e9-b3c2-e2e99ad9b241","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bdd6db63-13f7-5183-a3a2-63b619818fb3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d44a69c-3824-5509-a756-cda3bc1bd50a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e5526ef2-c93a-595d-a0c1-8068bad91f10","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0092236d-21ec-5777-85c0-6e95f9962a15","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8791b380-0e55-5489-987e-5db590030323","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc36d12c-c9a8-5970-8b4b-74304413a1f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"98eac615-b29a-5de3-a795-37b42615eb61","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1bba7c83-ac64-5978-aee5-3cde27c01da3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4a1541cc-8e89-4d22-b3d5-a77700838895 --><h3>Contraindications and cautions</h3><!-- end field 4a1541cc-8e89-4d22-b3d5-a77700838895 -->","summary":"","htmlStringContent":"<!-- begin item 8939012d-edf4-40a3-9396-a77700838594 --><!-- begin field ead6dddc-d468-42fa-ad68-a77700838895 --><ul><li><strong>Do not prescribe quinolones to:</strong><ul><li>Pregnant women — quinolone has been shown to cause arthropathy in animal studies.</li><li>Breastfeeding women — quinolones are excreted in breast milk.</li></ul></li><li><strong>Prescribe quinolones with caution to people with:</strong><ul><li>Epilepsy, or conditions that predispose to seizures, and in people taking other medication that may predispose to seizures, as quinolones can lower the seizure threshold.<ul><li>Quinolones may induce convulsions in patients with or without a history of convulsions, and taking NSAIDs at the same time may also induce them.</li><li>A single dose for treatment of gonorrhoea is unlikely to be significant.</li></ul></li><li>People with a history of tendonitis — quinolones can very rarely cause tendon damage, and the risk of tendon rupture is increased by co-administration of corticosteroid.<ul><li>A single dose for treatment of gonorrhoea is unlikely to be significant.</li></ul></li><li>Impaired renal function — dose adjustments may be required. </li><li>Impaired liver function — liver damage can occur. </li><li>Conditions which predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia, or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li><li>Positive family history of aneurysm disease or congenital heart valve disease.</li><li>Pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing for:<ul><li>Both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet's disease, hypertension, rheumatoid arthritis) <em>or additionally</em></li><li>Aortic aneurysm and dissection (such as vascular disorders including Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sjögren's syndrome) <em>or additionally</em></li><li>Heart valve regurgitation/incompetence (such as infective endocarditis).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2020</a>]</p><!-- end field ead6dddc-d468-42fa-ad68-a77700838895 --><!-- end item 8939012d-edf4-40a3-9396-a77700838594 -->","subChapters":[]},{"id":"a5f5d4c9-1e26-582f-8924-f04a3cb7b14d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e13c4754-bb6d-45fa-bd08-a7770083e229 --><h3>Adverse effects</h3><!-- end field e13c4754-bb6d-45fa-bd08-a7770083e229 -->","summary":"","htmlStringContent":"<!-- begin item 338f2e1d-c8c2-4e76-adfb-a7770083e000 --><!-- begin field 6881a5b5-fe22-4075-9412-a7770083e229 --><ul><li><strong>Adverse effects of quinolones include:</strong><ul><li><strong>Gastrointestinal effects</strong> (1–10% of people) — for example diarrhoea and nausea. May be slightly less common with ofloxacin.</li><li><strong>Musculoskeletal </strong>(very rare) — tendon damage. The risk of tendon rupture is increased by co-administration of corticosteroids.</li><li><strong>Antibiotic-associated colitis</strong> (rare). </li><li><strong>Pseudomembranous colitis</strong> (very rare) — consider this if a person develops severe diarrhoea during or after treatment with ofloxacin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Central nervous system </strong>— Quinolones may lower the seizure threshold and may trigger seizures. Quinolones should be used with extreme caution in patients predisposed to seizures. In addition drowsiness and impaired performance of skilled tasks (such as driving) can be occasionally caused by ofloxacin. Advise the person to use caution when driving a car or operating machinery.  </li><li><strong>Cardiovascular system</strong> — there is an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</li><li>Other adverse effects include: <ul><li>Uveitis. </li><li>Severe liver injury.</li><li>Exfoliative dermatitis (frequency unknown).</li></ul></li></ul></li><li><strong>NOTE: </strong>fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">MHRA, 2019</a>] </p><!-- end field 6881a5b5-fe22-4075-9412-a7770083e229 --><!-- end item 338f2e1d-c8c2-4e76-adfb-a7770083e000 -->","subChapters":[]},{"id":"e9b86103-d982-5ff9-81e2-51de8f4ba848","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b0e55bcb-e478-4c72-8a0e-a777008411fa --><h3>Drug interactions</h3><!-- end field b0e55bcb-e478-4c72-8a0e-a777008411fa -->","summary":"","htmlStringContent":"<!-- begin item 02226c2a-0985-49f0-87e3-a77700840f38 --><!-- begin field 7e785039-6c17-4227-945f-a777008411fa --><ul><li><strong>Possible drug interactions include: </strong><ul><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li><li><strong>Antacids </strong>— should preferably not be taken at the same time as quinolones as they may impair its absorption.</li><li><strong>Coumarins </strong>— quinolones may enhance the anticoagulant effect, increasing the risk of bleeding. Check the INR within 3–5 days of starting the quinolone.<ul><li>Advise people taking warfarin to seek immediate medical advice if they experience spontaneous bleeding, and the bleeding does not stop or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, and blood in the urine or stools.</li></ul></li><li><strong>Theophylline </strong>— ciprofloxacin increases the plasma concentration of theophylline, leading to possible increased risk of convulsions. There is the possibility of a similar effect with ofloxacin. Monitor theophylline concentration closely.</li><li><strong>Tizanidine </strong>— ciprofloxacin increases the plasma concentration of tizanidine (increased risk of toxicity). Other quinolones may also interact.</li><li><strong>Ciclosporin </strong>— increased risk of nephrotoxicity when quinolones are given with ciclosporin. This interaction occurs very occasionally and unpredictably, but it would be prudent to bear in mind during concurrent use.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Phenytoin</strong> — concurrent administration of ciprofloxacin can cause an increase or decrease in serum phenytoin levels.</li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Zinc </strong>— the absorption of ciprofloxacin and ofloxacin is reduced by zinc.</li><li><strong>Zolmitriptan </strong>— quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016c</a>] </p><!-- end field 7e785039-6c17-4227-945f-a777008411fa --><!-- end item 02226c2a-0985-49f0-87e3-a77700840f38 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}